Compare ATOM & ANIK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATOM | ANIK |
|---|---|---|
| Founded | 2001 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 189.2M | 191.4M |
| IPO Year | 2016 | 1996 |
| Metric | ATOM | ANIK |
|---|---|---|
| Price | $8.81 | $15.34 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | ★ 2.2M | 104.0K |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 4.41 | ★ 80.16 |
| EPS | ★ N/A | N/A |
| Revenue | $62,000.00 | ★ $112,819,000.00 |
| Revenue This Year | $527.69 | $5.98 |
| Revenue Next Year | N/A | $7.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.89 | $7.90 |
| 52 Week High | $9.59 | $16.24 |
| Indicator | ATOM | ANIK |
|---|---|---|
| Relative Strength Index (RSI) | 79.31 | 56.77 |
| Support Level | $2.20 | $13.81 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.76 | 0.55 |
| MACD | 0.32 | -0.07 |
| Stochastic Oscillator | 84.13 | 45.61 |
Atomera Inc is engaged in the business of developing, commercializing, and licensing proprietary processes and technologies for the semiconductor industry. The company's technology, named Mears Silicon Technology, or MST, is a thin film of re-engineered silicon, typically 100 to 300 angstroms (or approximately 20 to 60 silicon atomic unit cells) thick. MST can be applied as a transistor channel enhancement to CMOS-type transistors, the majority of widely used in the semiconductor industry. The company's silicon technology can be used for applications like Analog, DRAM, logic, processors, and SRAM. Geographically, it generates maximum revenue from North America.
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.